Adamis Pharmaceuticals (ADMP) Receiving Somewhat Favorable Media Coverage, Report Shows
News coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adamis Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.8568438790806 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Adamis Pharmaceuticals (NASDAQ:ADMP) traded down $0.10 on Monday, reaching $4.75. 556,400 shares of the company were exchanged, compared to its average volume of 736,100. Adamis Pharmaceuticals has a 52-week low of $2.80 and a 52-week high of $6.45. The stock has a market capitalization of $156.92, a PE ratio of -6.79 and a beta of 0.33. The company has a current ratio of 3.93, a quick ratio of 3.79 and a debt-to-equity ratio of 0.06.
A number of brokerages recently weighed in on ADMP. Maxim Group set a $14.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 30th. Raymond James Financial began coverage on shares of Adamis Pharmaceuticals in a research report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price target for the company. ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $10.33.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/adamis-pharmaceuticals-admp-receiving-somewhat-favorable-media-coverage-report-shows/1798742.html.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.